Zoetis Inc. Earnings Recaps
Q1 2026
May 9, 2026
Zoetis shares dropped 25.5% following earnings as investors reacted to an unexpectedly weak U.S. companion animal segment marked by demand softness, increased price sensitivity, intensified competitive pressures, and lack of market expansion that together pressured revenue and margins.
Key takeaways
- Organic operational revenue was flat overall; U.S. revenue declined 8% while International grew 10%.
- Companion animal segment fell 4% operationally, driven by weaker demand for premium preventative and chronic care products amid softer clinic traffic and higher price sensitivity.
- Key franchises like dermatology and Simparica suffered share loss due to aggressive competitor pricing and prolonged promotional activity, particularly in the U.S.
- Livestock segment delivered 12% organic operational growth, partially offsetting the weakness in companion animal.
- Management anticipates pipeline-driven growth beyond 2027 but near-term results reflect increased exposure to the challenged premium pet care market and cautious spending trends.
Q3 2025
Nov 6, 2025
Zoetis delivered solid third-quarter results with a 4% revenue increase and a 9% rise in adjusted net income, showcasing resilience through a diverse product portfolio despite facing macroeconomic headwinds.
Key takeaways
- Organic operational revenue growth of 6% in the International segment, with U.S. growth at 3% excluding the MFA divestiture.
- Companion Animal revenue rose 2%, while Livestock revenue surged 10% driven by strong market demand.
- The Simparica franchise saw 7% growth, supported by international momentum and recent approvals enhancing market reach.
- A decline of 11% in osteoarthritis franchise sales indicates challenges, with focused strategies in place for recovery.
- Upcoming product launches, including Lenivia and Portela, expected to reinforce Zoetis' leadership in chronic pain management.